Surveillance of antibiotic utilization and bacterial resistance profiles in tertiary level hospitals in Mexico City;Vigilancia de los niveles de uso de antibióticos y perfiles de resistencia bacteriana en hospitales de tercer nivel de la Ciudad de México

Salud Publica de Mexico

Volumn 47, Issue 3, 2005, Pages 219-226

  Benavides Plascencia, Lilia ^a   Aldama Ojeda, Alejandro Leonardo ^b   Vázquez, Héctor Javier ^b  

^a DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^b UNIVERSIDAD AUTÓNOMA METROPOLITANA AZCAPOTZALCO   (Mexico)

Author keywords

Antibiotics; Mexico; Resistance microbial

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEPHALOSPORIN; GLYCOPEPTIDE; LINCOSAMIDE; MACROLIDE; MONOBACTAM; NITROFURAN; SULFONAMIDE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG SURVEILLANCE PROGRAM; DRUG USE; DRUG UTILIZATION; HOSPITAL INFECTION; MEXICO; QUALITY CONTROL;

EID: 23744456095     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0036-36342005000300005     Document Type: Article

References (39)

1. Levy SB. The antibiotic paradox. 2nd. edition. Cambridge (MA): Perseus Publishing; 2002.
2. Buckwold FJ, Ronald AR. Antimicrobial misuse-effects and suggestions for control. J Antimicrob Chemother 1979;5:129-136.
3. Avom J, Solomon DH. Cultural and economical factors that (mis)shape antibiotic use: The nonpharmacologic basis of therapeutics. Ann Intern Med 2000;133:128-135.
4. Huges VM, Dotta N. Conjugative plasmids in bacteria of the "pre-antibiotic" era. Nature 1983;302:725-726.
5. Behra-Miellet J, Calvet L, Mory F, Muller C, Chomarat M, Bézian MC et al. Antibiotic-resistance among anaerobic gram-negative bacilli: Lessons from a french multicentric survey. Anaerobe 2003;9:105.
6. Heinemann JA, Ankenbauer B, Amábile-Cuevas CF. Do antibiotics maintain antibiotic resistance? Drug Discov Today 2000;5:195-204.
7. Kunin CM. Evaluation of antibiotic usage: A comprehensive look at alternative approaches. Rev Infect Dis 1981;3:745-753.
8. Beaber JW, Hochhut B, Waldor MK. SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature 2004;427:72-74.
9. Amábile-Cuevas CF, ed. Multiple drug resistant bacteria. Londres: Horizon Scientific Press; 2003.
10. McGowan Jr JE. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983;5:1033-1048.
11. McGowan Jr JE. Is antimicrobial resistance in hospital microorganisms related to antibiotic use? Bull NY Acad Med 1987;63:253-268.
12. Cooke D, Salter AJ, Phillips I. Antimicrobial misuse, antibiotic policies and information resourses. J Antimicrob Chemother 1980;6:435-443.
13. Gerding DN, Larson TA, Hughes RA, Weiler M, Shankoltzer C, Peterson LR. Aminoglycoside resistance and aminoglycoside usage: Ten years of experience in one hospital. Antimicrob Agents Chemother 1991;35:1284-1290.
14. Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC programme in North America. J Antimicrob Chemother 2004;53:290-296.
15. Lipsitch M, Bergstrom CT, Levin BR. The epidemiology of antibiotic resistance in hospitals: Paradoxes and prescriptions. Proc Natl Acad Sci USA 2000;97:1938-1943.
16. Lesch CA, Itokaszu GS, Danziger LH. Multi-hospital analysis of antimicrobial usage and resistance trends. Diagn Microbiol Infect Dis 2001;41:149-154.
17. Rubin MA, Samore MH. Antimicrobial use and resistance. Curr Infect Dis Rep 2002;4:491-497.
18. Levin BR, Lipsitch M, Perrot V, Schrag S, Antia R, Simonsen L et al. The population genetics of antibiotic resistance. Clin Infect Dis 1997;24 (Suppl 1):S9-S16.
19. Monnet DL, Archibald LK, Phillips L, Tenover FC, McGowan JE Jr, Gaynes RP. Antimicrobial use and resistance in eight US hospitals: Complexities of analysis and modeling. Infect Control Hosp Epidemiol 1998;19:388-394.
20. Guillemot D. Antibiotic use in humans and bacterial resistance. Curr Opin Microbiol 1999;2:494-498.
21. López-Lozano JM, Monnet DL, Yague A, Burgos A, Gonzalo N, Campillo P et al. Modeling and forecasting antimicrobial resístance and its dynamic relationship to antimicrobial use: A time series analysis. Int J Antimicrob Agents 2000;14:21-31.
22. Monnet DL, López-Lozano JM, Campillos P, Burgos A, Yague A, Gonzalo N. Making sense of antimicrobial use and resistance surveillance data: Application of ARIMA and transfer function models. Eur Soc Clin Microbiol Infect Dis 200l;7(Suppl 5):S29-S36.
23. Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: A population perspective. Emerg Infect Dis 2002;8:347-354.
24. Shlaes DM, Dale N, Gerding MD, Joseph F, John Jr MD, William A et al. Society for Health Care Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275-291.
25. Patton KA. Role of JCAHO standards and clinical practice guidelines in promoting appropriate antimicrobial use. Am J Health Syst Pharm 2002;59 (Suppl 3):S16-S18.
26. United States General Accounting Office. Antimicrobial resistance. Data to assess public health threat from resistant bacteria are limited. GAO/HEHS/NSIAD/RCED-99-132. Disponible en: http://www.gao.gov/ archive/1999/hx99132.pdf.
27. Department of Health. The path of least resistance. Main report. Standing Medical Advisory Committee. Sub-group on antimicrobial resistance. Londres: Department of Health. Publication Unit PHLS. Headquarters Office; 1998. Disponible en: http://www.doh.gov.uk/ smacful.htm.
28. Organización Panamericana de la Salud. Prevención y control de la resistencia a los antimicrobianos en las Américas. Plan estratégico de vigilancia de la resistencia a los antibióticos. OPS/HCP/HCT/139/99. Disponible en: http://www.paho.org/Spanish/HCP/HCT/EER/ PlanRegionalParaguay.doc.
29. World Health Organization. Antibiotic resistance: Synthesis of recommendations by expert policy groups (1987-2000). WHO.APUA,USAID.World Health Organization; 2001. Disponible en: http://www.who.int/csr/resources/ publication/drugresist/ antibiotics.pdf/.
30. World Health Organization. WHO Global Strategy for Containment of Antimicrobial Resistance. WHO/CDS/CSR/DRS/2001/2/EN. Disponible en: http://www.who.int/csr/resources/publication/drugresist/ WHO_CDS_CSR_DRS_2001_2_EN/en/.
31. Mendenhall W, Beaver RJ, Beaver BM. Introducción a la probabilidad y estadística. México: Thomson Learning; 2000: 248.
32. ABC Calc 1.8_2. European Study Group on Antibiotic Policies. ESGAP. Disponible en: www.escmid.org/sgwp.esgap2/ esgap_abc_calc_introduc.html.
33. Thomson PLM. Diccionario de especialidades farmacéuticas. Edición 48. México, DF: Ediciones PLM; 2002.
34. Gaynes R. The impact of antimicrobial use on the emergence of antimicrobial-resistant bacteria in hospitals. Infect Dis Clin North Am 1997;11:757-765.
35. Medina-Cuevas F, Navarrete-Navarro S, Avila-Figueroa C, Santos-Preciado JI. FARMAC programa diseñado para vigilar la prescripción de antimicrobianos en hospitales. Gac Med Mex 2000;136:107-111.
36. Calva JJ, Niebla-Pérez A, Rodríguez-Lemoine V, Santos JI, Amábile-Cuevas CF. Antibiotic usage and antibiotic resistance in Latin America. En: Amábile-Cuevas CF, comp. Antibiotic resistance: From molecular basics to therapeutic options. Nueva York: Chapman & Hall; 1996:73-97.
37. Gums JG, Yancey RW Jr, Hamilton CA, Kubilis PS. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy 1999;19:1369-1377.
38. Food and Drugs Administration. Department of Health and Human Services. Antimicrobial resistance as a Public Health Issue. Henney JE. Commissioner of Food and Drugs. FDA. Department of Health and Human Services; 2000. Disponible en: http:/www.hhs.gov/asl/testify/ t000920c.html.
39. Goldmann DA, Huskins WC. Control of nosocomial antimicrobial-resistant bacteria: A strategic priority for hospitals worldwide. Clin Infect Dis 1997;24(Suppl 1):S139-S145.